Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study
A total of 50 patients with advanced pancreatic cancer were enrolled in a phase II study of bevacizumab 15 mg kg −1 , capecitabine 1300 mg m −2 daily for 2 weeks and gemcitabine 1000 mg m −2 weekly 2 times; cycles were repeated every 21 days. Radiological response rate was 22%; progression-free surv...
Gespeichert in:
Veröffentlicht in: | British journal of cancer 2009-06, Vol.100 (12), p.1842-1845 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1845 |
---|---|
container_issue | 12 |
container_start_page | 1842 |
container_title | British journal of cancer |
container_volume | 100 |
creator | Javle, M Yu, J Garrett, C Pande, A Kuvshinoff, B Litwin, A Phelan, J Gibbs, J Iyer, R |
description | A total of 50 patients with advanced pancreatic cancer were enrolled in a phase II study of bevacizumab 15 mg kg
−1
, capecitabine 1300 mg m
−2
daily for 2 weeks and gemcitabine 1000 mg m
−2
weekly 2 times; cycles were repeated every 21 days. Radiological response rate was 22%; progression-free survival and over survival were 5.8 and 9.8 months respectively. Grade 3 or 4 toxicities included neutropaenia (22%), thrombocytopaenia (14%), thromboembolic events (12%), hypertension (8%) and haemorrhage (6%). |
doi_str_mv | 10.1038/sj.bjc.6605099 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2714236</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1745316351</sourcerecordid><originalsourceid>FETCH-LOGICAL-c507t-f53a99d523d53664a758f232d18b2c38b953bdf73f36826879f6d682d04d9fc33</originalsourceid><addsrcrecordid>eNp1kctvFDEMxiNERZfClRsoQuI42zzmZQ6VoAK6UqVe4Bx58tjNaOdBMrOo_PWk2mELh56c2D9_tvwR8oazNWeyvoztumn1uixZwQCekRUvpMh4LarnZMUYqzIGgp2TlzG26Qusrl6Qcw45cGD5imw_2wNq_3vusKF66BrfW0N_-WlHt7bTfsKHDMXeUI2jPSXcECiaA_Y64WMKweLkdYJSJnykSMcdRks3Gxqn2dy_ImcO99G-XuIF-fH1y_frm-z27tvm-tNtpgtWTZkrJAKYQkhTyLLMsSpqJ6QwvG6ElnUDhWyMq6STZS3KugJXmvQyLDfgtJQX5OqoO85NZ422_RRwr8bgOwz3akCv_q_0fqe2w0GJiudClkng_SIQhp-zjZNqhzn0aWclBABImUOC1kdIhyHGYN1pAGfqwRcVW5V8UYsvqeHdv2s94osRCfiwABg17l1Id_TxxAkOsmbAE3d55GIq9VsbHtd7cvTbY0eP0xzsSfJv_Q9CmbFS</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>229993349</pqid></control><display><type>article</type><title>Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study</title><source>MEDLINE</source><source>SpringerLink Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Nature Journals Online</source><source>PubMed Central</source><creator>Javle, M ; Yu, J ; Garrett, C ; Pande, A ; Kuvshinoff, B ; Litwin, A ; Phelan, J ; Gibbs, J ; Iyer, R</creator><creatorcontrib>Javle, M ; Yu, J ; Garrett, C ; Pande, A ; Kuvshinoff, B ; Litwin, A ; Phelan, J ; Gibbs, J ; Iyer, R</creatorcontrib><description>A total of 50 patients with advanced pancreatic cancer were enrolled in a phase II study of bevacizumab 15 mg kg
−1
, capecitabine 1300 mg m
−2
daily for 2 weeks and gemcitabine 1000 mg m
−2
weekly 2 times; cycles were repeated every 21 days. Radiological response rate was 22%; progression-free survival and over survival were 5.8 and 9.8 months respectively. Grade 3 or 4 toxicities included neutropaenia (22%), thrombocytopaenia (14%), thromboembolic events (12%), hypertension (8%) and haemorrhage (6%).</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/sj.bjc.6605099</identifier><identifier>PMID: 19491904</identifier><identifier>CODEN: BJCAAI</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal - administration & dosage ; Antibodies, Monoclonal, Humanized ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Bevacizumab ; Biological and medical sciences ; Biomedical and Life Sciences ; Biomedicine ; Cancer Research ; Capecitabine ; Deoxycytidine - administration & dosage ; Deoxycytidine - analogs & derivatives ; Drug Resistance ; Epidemiology ; Female ; Fluorouracil - administration & dosage ; Fluorouracil - analogs & derivatives ; Gastroenterology. Liver. Pancreas. Abdomen ; Humans ; Liver Neoplasms - drug therapy ; Liver Neoplasms - secondary ; Liver. Biliary tract. Portal circulation. Exocrine pancreas ; Lung Neoplasms - drug therapy ; Lung Neoplasms - secondary ; Lymphatic Metastasis ; Male ; Medical sciences ; Middle Aged ; Molecular Medicine ; Oncology ; Pancreatic cancer ; Pancreatic Neoplasms - drug therapy ; Pancreatic Neoplasms - pathology ; Prognosis ; Short Communication ; Survival Rate ; Treatment Outcome ; Tumors</subject><ispartof>British journal of cancer, 2009-06, Vol.100 (12), p.1842-1845</ispartof><rights>The Author(s) 2009</rights><rights>2009 INIST-CNRS</rights><rights>Copyright Nature Publishing Group Jun 16, 2009</rights><rights>Copyright © 2009 Cancer Research UK 2009 Cancer Research UK</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c507t-f53a99d523d53664a758f232d18b2c38b953bdf73f36826879f6d682d04d9fc33</citedby><cites>FETCH-LOGICAL-c507t-f53a99d523d53664a758f232d18b2c38b953bdf73f36826879f6d682d04d9fc33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2714236/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2714236/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,2727,27924,27925,41488,42557,51319,53791,53793</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21938091$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19491904$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Javle, M</creatorcontrib><creatorcontrib>Yu, J</creatorcontrib><creatorcontrib>Garrett, C</creatorcontrib><creatorcontrib>Pande, A</creatorcontrib><creatorcontrib>Kuvshinoff, B</creatorcontrib><creatorcontrib>Litwin, A</creatorcontrib><creatorcontrib>Phelan, J</creatorcontrib><creatorcontrib>Gibbs, J</creatorcontrib><creatorcontrib>Iyer, R</creatorcontrib><title>Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><addtitle>Br J Cancer</addtitle><description>A total of 50 patients with advanced pancreatic cancer were enrolled in a phase II study of bevacizumab 15 mg kg
−1
, capecitabine 1300 mg m
−2
daily for 2 weeks and gemcitabine 1000 mg m
−2
weekly 2 times; cycles were repeated every 21 days. Radiological response rate was 22%; progression-free survival and over survival were 5.8 and 9.8 months respectively. Grade 3 or 4 toxicities included neutropaenia (22%), thrombocytopaenia (14%), thromboembolic events (12%), hypertension (8%) and haemorrhage (6%).</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antibodies, Monoclonal - administration & dosage</subject><subject>Antibodies, Monoclonal, Humanized</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Bevacizumab</subject><subject>Biological and medical sciences</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer Research</subject><subject>Capecitabine</subject><subject>Deoxycytidine - administration & dosage</subject><subject>Deoxycytidine - analogs & derivatives</subject><subject>Drug Resistance</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Fluorouracil - administration & dosage</subject><subject>Fluorouracil - analogs & derivatives</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Humans</subject><subject>Liver Neoplasms - drug therapy</subject><subject>Liver Neoplasms - secondary</subject><subject>Liver. Biliary tract. Portal circulation. Exocrine pancreas</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - secondary</subject><subject>Lymphatic Metastasis</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Molecular Medicine</subject><subject>Oncology</subject><subject>Pancreatic cancer</subject><subject>Pancreatic Neoplasms - drug therapy</subject><subject>Pancreatic Neoplasms - pathology</subject><subject>Prognosis</subject><subject>Short Communication</subject><subject>Survival Rate</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kctvFDEMxiNERZfClRsoQuI42zzmZQ6VoAK6UqVe4Bx58tjNaOdBMrOo_PWk2mELh56c2D9_tvwR8oazNWeyvoztumn1uixZwQCekRUvpMh4LarnZMUYqzIGgp2TlzG26Qusrl6Qcw45cGD5imw_2wNq_3vusKF66BrfW0N_-WlHt7bTfsKHDMXeUI2jPSXcECiaA_Y64WMKweLkdYJSJnykSMcdRks3Gxqn2dy_ImcO99G-XuIF-fH1y_frm-z27tvm-tNtpgtWTZkrJAKYQkhTyLLMsSpqJ6QwvG6ElnUDhWyMq6STZS3KugJXmvQyLDfgtJQX5OqoO85NZ422_RRwr8bgOwz3akCv_q_0fqe2w0GJiudClkng_SIQhp-zjZNqhzn0aWclBABImUOC1kdIhyHGYN1pAGfqwRcVW5V8UYsvqeHdv2s94osRCfiwABg17l1Id_TxxAkOsmbAE3d55GIq9VsbHtd7cvTbY0eP0xzsSfJv_Q9CmbFS</recordid><startdate>20090616</startdate><enddate>20090616</enddate><creator>Javle, M</creator><creator>Yu, J</creator><creator>Garrett, C</creator><creator>Pande, A</creator><creator>Kuvshinoff, B</creator><creator>Litwin, A</creator><creator>Phelan, J</creator><creator>Gibbs, J</creator><creator>Iyer, R</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>20090616</creationdate><title>Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study</title><author>Javle, M ; Yu, J ; Garrett, C ; Pande, A ; Kuvshinoff, B ; Litwin, A ; Phelan, J ; Gibbs, J ; Iyer, R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c507t-f53a99d523d53664a758f232d18b2c38b953bdf73f36826879f6d682d04d9fc33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antibodies, Monoclonal - administration & dosage</topic><topic>Antibodies, Monoclonal, Humanized</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Bevacizumab</topic><topic>Biological and medical sciences</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer Research</topic><topic>Capecitabine</topic><topic>Deoxycytidine - administration & dosage</topic><topic>Deoxycytidine - analogs & derivatives</topic><topic>Drug Resistance</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Fluorouracil - administration & dosage</topic><topic>Fluorouracil - analogs & derivatives</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Humans</topic><topic>Liver Neoplasms - drug therapy</topic><topic>Liver Neoplasms - secondary</topic><topic>Liver. Biliary tract. Portal circulation. Exocrine pancreas</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - secondary</topic><topic>Lymphatic Metastasis</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Molecular Medicine</topic><topic>Oncology</topic><topic>Pancreatic cancer</topic><topic>Pancreatic Neoplasms - drug therapy</topic><topic>Pancreatic Neoplasms - pathology</topic><topic>Prognosis</topic><topic>Short Communication</topic><topic>Survival Rate</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Javle, M</creatorcontrib><creatorcontrib>Yu, J</creatorcontrib><creatorcontrib>Garrett, C</creatorcontrib><creatorcontrib>Pande, A</creatorcontrib><creatorcontrib>Kuvshinoff, B</creatorcontrib><creatorcontrib>Litwin, A</creatorcontrib><creatorcontrib>Phelan, J</creatorcontrib><creatorcontrib>Gibbs, J</creatorcontrib><creatorcontrib>Iyer, R</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Javle, M</au><au>Yu, J</au><au>Garrett, C</au><au>Pande, A</au><au>Kuvshinoff, B</au><au>Litwin, A</au><au>Phelan, J</au><au>Gibbs, J</au><au>Iyer, R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study</atitle><jtitle>British journal of cancer</jtitle><stitle>Br J Cancer</stitle><addtitle>Br J Cancer</addtitle><date>2009-06-16</date><risdate>2009</risdate><volume>100</volume><issue>12</issue><spage>1842</spage><epage>1845</epage><pages>1842-1845</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><coden>BJCAAI</coden><abstract>A total of 50 patients with advanced pancreatic cancer were enrolled in a phase II study of bevacizumab 15 mg kg
−1
, capecitabine 1300 mg m
−2
daily for 2 weeks and gemcitabine 1000 mg m
−2
weekly 2 times; cycles were repeated every 21 days. Radiological response rate was 22%; progression-free survival and over survival were 5.8 and 9.8 months respectively. Grade 3 or 4 toxicities included neutropaenia (22%), thrombocytopaenia (14%), thromboembolic events (12%), hypertension (8%) and haemorrhage (6%).</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>19491904</pmid><doi>10.1038/sj.bjc.6605099</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0007-0920 |
ispartof | British journal of cancer, 2009-06, Vol.100 (12), p.1842-1845 |
issn | 0007-0920 1532-1827 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2714236 |
source | MEDLINE; SpringerLink Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Nature Journals Online; PubMed Central |
subjects | Adult Aged Aged, 80 and over Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bevacizumab Biological and medical sciences Biomedical and Life Sciences Biomedicine Cancer Research Capecitabine Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives Drug Resistance Epidemiology Female Fluorouracil - administration & dosage Fluorouracil - analogs & derivatives Gastroenterology. Liver. Pancreas. Abdomen Humans Liver Neoplasms - drug therapy Liver Neoplasms - secondary Liver. Biliary tract. Portal circulation. Exocrine pancreas Lung Neoplasms - drug therapy Lung Neoplasms - secondary Lymphatic Metastasis Male Medical sciences Middle Aged Molecular Medicine Oncology Pancreatic cancer Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - pathology Prognosis Short Communication Survival Rate Treatment Outcome Tumors |
title | Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T21%3A05%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bevacizumab%20combined%20with%20gemcitabine%20and%20capecitabine%20for%20advanced%20pancreatic%20cancer:%20a%20phase%20II%20study&rft.jtitle=British%20journal%20of%20cancer&rft.au=Javle,%20M&rft.date=2009-06-16&rft.volume=100&rft.issue=12&rft.spage=1842&rft.epage=1845&rft.pages=1842-1845&rft.issn=0007-0920&rft.eissn=1532-1827&rft.coden=BJCAAI&rft_id=info:doi/10.1038/sj.bjc.6605099&rft_dat=%3Cproquest_pubme%3E1745316351%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=229993349&rft_id=info:pmid/19491904&rfr_iscdi=true |